ANTEOTECH LTD (ASX: ADO)
Health care · News and insights
Price unavailable
Latest ADO announcements
Announcement Insights
AnteoTech Revenue Halves as Sales Conversion Becomes Priority
AnteoTech’s FY2026 revenue fell to about $468,000 from about $969,000, prompting management to make converting its customer pipeline into sales the company’s top priority. The decline was partly attributed to a Serum Institute shipment moving into July; the company reported cash expenses down 19% and finished the year with $11 million in cash and no debt, while battery and diagnostics evaluations continued.
Updated 16 Nov 2026, 03:55 PM Sydney time
Sources
Notification of cessation of securities - ADONotification regarding unquoted securities - ADOChange of Director's Interest Notice x 3Application for quotation of securities - ADOChair's Address to ShareholdersManaging Director AGM PresentationResults of MeetingQuarterly Activities/Appendix 4C Cash Flow ReportAppointment of CFO and Company SecretaryComments
2026-11-16 · Health care
ADO: $0.016 -5.88% · MC: $56M
AnteoTech reported that five million unquoted options lapsed after the conditions attached to them were not met or became impossible to satisfy. The lapse leaves no options in that class outstanding; the company’s ordinary share count is unchanged in the notice.
Updated 2026-11-16 15:50
Sources
Notification of cessation of securities - ADOComments
2026-11-12 · Health care
ADO: $0.017 +0.00% · MC: $56M
AnteoTech issued its managing director 2.3 million shares under the FY2026 incentive plan and granted long-term options to its CEO and directors, following shareholder approval at the AGM. The shares were issued for no cash consideration, and the options are exercisable at 3.75 cents through November 2030.
Updated 2026-11-12 10:13
Sources
Notification regarding unquoted securities - ADOChange of Director's Interest Notice x 3Comments
2026-11-11 · Health care
ADO: $0.017 +0.00% · MC: $56M
AnteoTech issued ordinary shares to Managing Director and CEO Merrill Gray under its employee incentive plan for FY2026 short-term incentive outcomes. The shares were issued for no cash consideration and rank equally with existing ordinary shares.
Updated 2026-11-11 16:16
Sources
Application for quotation of securities - ADOComments
2026-11-10 · Health care
ADO: $0.017 +6.25% · MC: $56M
At its 2026 AGM, AnteoTech said converting its customer pipeline into sales is its top priority after FY2026 revenue fell to about $468,000 from about $969,000, partly because a Serum Institute shipment shifted into July. The company reported cash expenses down 19% and ended the year with $11 million in cash and no debt; it also highlighted battery and diagnostics progress, including Ultranode 95 testing and ongoing customer evaluations. All AGM resolutions were passed.
Updated 2026-11-10 17:09
Sources
Chair's Address to ShareholdersManaging Director AGM PresentationResults of MeetingComments
2026-10-29 · Health care
ADO: $0.016 +14.29% · MC: $56M
AnteoTech reported expanded customer evaluations and commercial activity across its battery and life sciences businesses, including agreements with Xerabrid and Airspeeder and progress on a collaboration with a global life sciences company. It received approximately $2 million in research and development tax incentives and ended the quarter with $11 million in cash and cash equivalents, including $5.5 million on term deposit, with no bank debt. The excerpt does not provide a prior-quarter cash figure for comparison.
Updated 2026-10-29 09:37
Sources
Quarterly Activities/Appendix 4C Cash Flow ReportComments
2026-10-28 · Health care
ADO: $0.014 -6.67% · MC: $56M
Luke Oxenham will take up the roles on 23 November, succeeding Scott Waddell, who resigned in September. Oxenham has more than 30 years of senior finance and corporate experience and most recently held the same roles at New Energy Opportunities.
Updated 2026-10-28 09:40
Sources
Appointment of CFO and Company SecretaryComments
Comments